Transgenic overexpression of FGF19 in mice elevated circulating FGF19 levels and subsequently reduced high-fat diet-induced weight gain, increased metabolic rate and improved obesity-associated metabolic defects, including insulin resistance, liver steatosis and plasma lipid levels [15], [16]. The gene discussed is FGF19; the disease is obesity due to melanocortin 4 receptor deficiency.